You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Cblb-based Drugs Against Sepsis and Inflammation

    SBC: CELL BIOLOGICS INC            Topic: NHLBI

    Abstract Septicemia poses a major health care challenge. Modern therapies requiring suppression of patients' immune systems, a growing numbers of elderly people in the population, and the emergence of drug-resistant bacteria, have increased the prevalenceand severity of the disease over the past few decades. Current treatments rely on drugs that do not significant reduce morbidity and mortali ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Corrosion Protection of High-Value Test&Evaluation Assets

    SBC: eSpin Technologies, Inc.            Topic: MDA13T010

    This STTR Phase I proposal proposes to design and develop reactive filter media using nanofiber technology to capture corrosion inducing particulate matter present in coastal region air. The fibrous filter media will be functionalized using ion exchange chemistry which is known to react with salt ions. The media will be characterized for its filtration performance, resistance to airflow, and dus ...

    STTR Phase I 2014 Department of DefenseMissile Defense Agency
  3. Developing Therapeutics That Target RAD51 to Treat Leukemia and Lymphoma

    SBC: Cyteir Therapeutics, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): Genomic instability is a hallmark of cancer, yet is underdeveloped as a therapeutic target area The central goal of this program is to develop new cancer therapeutics that target genomic instability as a hallmark of cancer cells, bringing new, cancer-cell selective treatments to the clinical oncology market. Two key challenges in current cancer therapy are mini ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Development of broad spectrum Hepatitis C Virus NS3/4A protease inhibitors

    SBC: NOVALEX THERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant This is a collaborative proposal to develop inhibitors with reduced susceptibility to resistance and improved genotype spectrum of activity against the NS A protease of the Hepatitis C virus HCV Over three percent of the worldandapos s population is infected with the hepatitis C virus HCV Unfortunately the current best treatment is still quite challeng ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Development of Compounds for the Prevention and Treatment of Rhabdomyolysis

    SBC: Virtual Drug Development Inc.            Topic: NIDDK

    ? DESCRIPTION (provided by applicant): The goal of this Phase I STTR project is to establish the feasibility of developing a small-molecule therapeutic agent designed to prevent rhabdomyolysis-induced renal failure. Rhabdomyolysis accounts for 7% to 10% of cases of renal failure in the US. Rhabdomyolysis results from muscle injury that leads to the release of myoglobin, which is then deposited ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Development of Novel S. aureus Antibiotics with Reduced Resistance Susceptibility

    SBC: NOVALEX THERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Widespread antibiotic use has accelerated S aureus resistance to almost all marketed antibiotic classes including beta lactams fluoroquinolones macrolides aminoglycosides tetracyclines as well as the newer linezolid and daptomycin Methicillin resistant S aureus MRSA is an increasing public health threat with deaths from MRSA infections already compar ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Engineering Cytolytic Effectors to Eliminate Virus-Infected and Cancer Cells

    SBC: IMMUVEN, INC.            Topic: NCI

    Project Summary The goal of this STTR grant application is to engineer powerful NK cell-based cytolytic effector cells for therapeutic applications. The cells will combine the selectivity and specificity of T cells and the ability of NK cells to mediate effective cytolytic activity against a wide spectrum of aberrant cells, including those with impaired adhesion properties. To achieve this goal we ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Microbial Surrogate Assay for Environmental PAH Exposure

    SBC: ARPHION LTD.            Topic: NIEHS

    DESCRIPTION (provided by applicant): Arphion is a company established to develop noninvasive products that will be used to diagnose, prevent, and treat head and neck and other cancers. 41,000 people are diagnosed with head and neck cancer (HNC) every yearin the United States, with 8,000 deaths. Tens of millions of people in the US are at increased risk for HNC due to exposure to the polycyclic ary ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Targeting DNA damage response pathways for the treatment of advanced lung cancer

    SBC: CUMBERLAND PHARMACEUTICALS INC.            Topic: NIEHS

    DESCRIPTION (provided by applicant): There is an urgent, unmet need for novel therapeutic approaches that are efficacious against lung cancer. Ranking first among cancer deaths in the U.S., this disease has 5-year relative survival rates of lt20%. Most lung cancers are non-small cell (NSCLC, 85% of cases). Curative surgery is not an option for the 80% of NSCLC patients who present with advanced s ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Top Coatings and Enhanced Cathodic Protection Capability for High-Value BMDS MDA Assets

    SBC: AMERICAN ENERGY TECHNOLOGIES COMPANY            Topic: MDA13T010

    American Energy Technologies Co. (a woman-owned small business concern of Arlington Heights, IL), will be joined by subcontractors University of Massachusetts (Boston, MA) and Advanced Technology Laboratories of Lockheed Martin Corp. (St. Paul, MN) in order to develop two anti-corrosion technologies with the goal to deploy them in a variety of equipment. The first technology is a top coating whic ...

    STTR Phase I 2014 Department of DefenseMissile Defense Agency
US Flag An Official Website of the United States Government